Icatibant Hikma

Icatibant, the active ingredient in Icatibant Hikma, is a bradykinin B2 receptor antagonist presented as a subcutaneous solution for subcutaneous use. It is indicated for the treatment of acute attacks of hereditary angioedema in patients with C1‑inhibitor deficiency, providing rapid reduction of swelling. The drug works by competitively blocking the bradykinin B2 receptor, thereby preventing the vasodilation and increased vascular permeability that cause edema.

GNH USA supplies Icatibant Hikma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Icatibant is used to treat hereditary angioedema by targeting the bradykinin pathway.

- Hereditary angioedema (C1‑inhibitor deficiency): provides rapid relief of acute swelling attacks. - Hereditary angioedema (type I and II): shortens the duration of facial and peripheral edema. - Hereditary angioedema abdominal attacks: reduces pain and gastrointestinal swelling associated with an episode.

Icatibant may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Injection site pain: mild to moderate discomfort at the injection site. - Redness or swelling at injection site: localized erythema or edema. - Nausea: transient gastrointestinal upset. - Headache: mild to moderate intensity. - Dizziness: temporary sensation of light‑headedness. - Fatigue: feeling of tiredness after administration.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Angioedema of the throat or airway: potentially life‑threatening swelling. - Severe hypotension: marked drop in blood pressure. - Thrombocytopenia: low platelet count observed in rare cases. - Stevens‑Johnson syndrome: severe skin reaction, extremely rare.

Before using Icatibant, consider the following safety measures.

- Pregnancy: safety not established; use only if potential benefit justifies the risk. - Breastfeeding: unknown safety; weigh benefits against possible infant exposure. - Renal impairment: use with caution; monitor renal function. - Concomitant ACE inhibitors or ARBs: may increase bradykinin levels; observe for enhanced edema. - Known hypersensitivity: discontinue immediately if severe allergic reaction occurs. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Icatibant can interact with other medicines that affect the bradykinin system or vascular tone.

Major Interactions (Avoid): - ACE inhibitors: may raise bradykinin levels and increase risk of angioedema. - Angiotensin II receptor blockers (ARBs): similar potential to augment bradykinin‑mediated effects.

Moderate Interactions (Monitor Closely): - Estrogen‑containing contraceptives: may influence HAE severity; monitor clinical response. - Non‑steroidal anti‑inflammatory drugs (NSAIDs): can exacerbate swelling; observe for increased attacks. - Other bradykinin antagonists: additive blockade may increase adverse effects; adjust therapy as needed.